Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-950 for Upper Limb Spasticity in Post-Stroke Patients
NCT05956509Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- Jan 2024
- Primary completion
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ABBV-950 in Upper limb spasticity (9 arms), sponsored by AbbVie Inc. Primary endpoints: Change From Baseline in Wrist Modified Ashworth Scale-Bohannon (MAS-B) at 6 weeks and Number of Participants Experiencing Adverse Events at 24 weeks. Started Jan 2024; status: terminated.
02
Drugs
ABBV-950
03
Conditions
Upper limb spasticity
Beyond the preview
Go deeper on NCT05956509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05956509.